SG Americas Securities LLC Has $16.64 Million Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)

SG Americas Securities LLC grew its position in Akero Therapeutics, Inc. (NASDAQ:AKRO) by 4,022.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 597,993 shares of the company’s stock after buying an additional 583,486 shares during the quarter. SG Americas Securities LLC’s holdings in Akero Therapeutics were worth $16,636,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of AKRO. Wellington Management Group LLP raised its position in Akero Therapeutics by 54.4% in the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock valued at $226,554,000 after buying an additional 2,782,029 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Akero Therapeutics by 2.9% in the third quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock valued at $203,053,000 after purchasing an additional 201,225 shares during the last quarter. RTW Investments LP lifted its position in shares of Akero Therapeutics by 9.0% in the third quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock worth $169,829,000 after purchasing an additional 487,450 shares in the last quarter. Perceptive Advisors LLC boosted its holdings in Akero Therapeutics by 8.1% during the second quarter. Perceptive Advisors LLC now owns 1,499,897 shares of the company’s stock worth $35,188,000 after purchasing an additional 112,426 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new position in Akero Therapeutics in the third quarter valued at $37,392,000.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on AKRO shares. Citigroup began coverage on shares of Akero Therapeutics in a research report on Monday, November 18th. They set a “buy” rating and a $65.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Akero Therapeutics in a report on Thursday, January 16th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.83.

Insider Activity at Akero Therapeutics

In other news, VP Patrick Lamy sold 925 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $30.79, for a total transaction of $28,480.75. Following the completion of the sale, the vice president now owns 17,858 shares in the company, valued at $549,847.82. The trade was a 4.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO William Richard White sold 2,817 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $30.79, for a total value of $86,735.43. Following the transaction, the chief financial officer now owns 38,335 shares in the company, valued at approximately $1,180,334.65. This trade represents a 6.85 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 262,135 shares of company stock worth $8,223,000. Company insiders own 7.94% of the company’s stock.

Akero Therapeutics Stock Up 4.6 %

Shares of AKRO stock opened at $26.16 on Friday. Akero Therapeutics, Inc. has a 52-week low of $15.32 and a 52-week high of $37.00. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -6.98 and a beta of -0.19. The firm’s 50-day moving average is $28.58 and its 200-day moving average is $28.06. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.15). Sell-side analysts predict that Akero Therapeutics, Inc. will post -3.96 EPS for the current year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.